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α2-Adrenoceptor agonist drugs, such as medetomidine, are widely used in 
veterinary medicine for their sedative and analgesic effects. However, α2-
adrenoceptor agonists have undesirable cardiovascular effects, most notably 
vasoconstriction and bradycardia. In view of this, vatinoxan (previously known 
as MK-467 and L-659’066) a peripherally acting α2-adrenoceptor antagonist 
has been investigated. Vatinoxan attenuates the negative cardiovascular 
effects of medetomidine in dogs while maintaining the sedative effects of the 
α2-adrenoceptor agonist.  
This thesis evaluated the effects of vatinoxan on the absorption and 
disposition of medetomidine and other selected drugs in laboratory and client-
owned dogs following intramuscular administration; when the drugs were 
combined in the same syringe. The hypothesis was that vatinoxan would affect 
the plasma concentrations of concomitantly administered drugs, probably due 
to changes in tonus of the vasculature at the injection site. Furthermore, the 
distribution of vatinoxan and medetomidine into the central nervous system 
(CNS) was investigated. It was hypothesized that in dogs, vatinoxan would 
minimally enter the CNS, whereas the enantiomers of medetomidine would 
concentrate there.  
A group of six laboratory beagles participated in the preclinical studies, and 57 
client-owned dogs were recruited into the clinical study. A randomized, clinical 
study was designed to investigate whether vatinoxan attenuates the 
bradycardic impact of medetomidine in client-owned dogs given 
medetomidine-butorphanol intramuscularly for minor diagnostic procedures.  
All analyses of drug concentrations were performed with liquid 
chromatography tandem mass spectrometry. Heart rates were monitored by 
auscultation and sedation was scored. Also, the degree of sedation was 
determined. It was hypothesized that vatinoxan would alleviate bradycardia 
without reducing the intensity of clinical sedation.  
8 
Vatinoxan initially increased plasma concentrations of concomitantly 
administered drugs. Improved cardiovascular performance in α2-adrenoceptor 
agonist-medicated dogs probably affected the absorption via improved blood 
flow in the muscle. Furthermore, the distribution of enantiomers of 
medetomidine into the CNS appeared to be high whereas only about 2% of 
the vatinoxan plasma concentration was detected in the CNS. Vatinoxan 
ameliorated medetomidine-induced bradycardia, but adequate clinical 
sedation with a faster onset and shorter duration was achieved. 
In conclusion, the increased absorption of concomitantly administered drugs 
by vatinoxan resulted in a quicker onset and shortened duration of the 
sedation. When vatinoxan was combined with medetomidine and butorphanol, 
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ABC  ATP-binding cassette, transporter superfamily 
AUC  Area under time response curve 
BBB  Blood-brain barrier 
BCRP  Breast cancer resistance protein (also known as ABCG2) 
BPM  Beats per minute 
BSCB  Blood-spinal cord barrier 
CL  Clearance 
Cmax  Maximum drug concentration in plasma 
CNS  Central nervous system 
CO  Cardiac output 
EDTA  Ethylenediaminetetraacetic acid 
HR  Heart rate 
IM  Intramuscular 
IV  Intravenous 
MAC  Minimum alveolar concentration 
MAP  Mean arterial pressure 
MATE  Multidrug and toxin extrusion transporter 
MDR  Multidrug resistance 
MRP  Multidrug resistance protein 
OAT  Organic anion transporter 
OCT  Organic cation transporter 
P-gp  P-glycoprotein (also known as ABCB1) 
pKa  The degree of ionization 
SD  Standard deviation 
SDS  Simple descriptive score, in this thesis used for assessing the sedation 
SLC  Solute carriers, transporter superfamily 
SVR  Systemic vascular resistance 
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T½  Half life 
Tmax  Time to Cmax 
VAS  Visual analogue scale 
Vz  Volume of distribution 






Sufficient delivery of a drug into the brain is essential when the target of the drug molecule 
is the central nervous system (CNS), as is the case with sedatives and anaesthetic drugs. 
The CNS is protected by blood-brain barrier (BBB) and blood-spinal cord barrier (BSCB): 
these physiological barriers provide a stable environment for neural function and protect the 
CNS from circulating neurotransmitters and xenobiotic substance. The challenge for a drug 
molecule is to pass these barriers. In addition to physiological properties of these barriers, 
the size and hydrophilicity of the molecule affects its ability to enter the CNS.   
α2-Adrenoceptor agonists are widely used in veterinary medicine for their sedative and 
anxiolytic properties, but their undesired cardiovascular effects, such as bradycardia and 
decreased cardiac output (CO), limit their usefulness. Medetomidine is a selective, potent 
and efficacious α2-adrenoceptor agonist that produces sedation and antinociception by 
stimulating α2-adrenoceptors in the central nervous system (Doze et al. 1989, Maze & 
Fujinaga 2000). Vasoconstriction is caused by activation of α2-adrenoceptors within vascular 
smooth muscle (Clough & Hatton 1981, Horn et al. 1982). Through a baroreceptor-mediated 
reflex, vasoconstriction leads to bradycardia which is responsible for a dramatic decrease in 
CO and oxygen delivery (Bloor et al. 1992, Pypendop 1998). 
In view of this, the ability of vatinoxan to attenuate the negative cardiovascular effects of 
dexmedetomidine and medetomidine in dogs has been investigated (Pagel et al. 1998, 
Enouri et al. 2008, Honkavaara et al. 2008, 2011). Vatinoxan predominantly blocks 
peripherally located α2-adrenoceptors due its limited ability to cross the BBB, as 
demonstrated in rats and marmosets (Clineschmidt et al. 1988). Therefore, it attenuates the 
initial vasoconstriction produced by α2-adrenoceptor agonist and the following 
haemodynamic disturbances  in dogs (Pagel et al. 1998, Enouri et al. 2008, Honkavaara et 
al. 2011), whereas the CNS effects of α2-agonists (sedation) are not decreased substantially 
(Pagel et al. 1998, Enouri et al 2008, Honkavaara et al 2008).  
Vatinoxan alters the disposition of α2-adrenoceptor agonists, an effect that probably results 
from  improvement of perfusion as demonstrated after intravenous (IV) administration to 
dogs (Honkavaara et al. 2012) but also inhibition of local vasoconstriction after intramuscular 
(IM) co-administration (Restitutti et al. 2017).  
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The studies reported in this thesis were designed to test the following hypotheses: vatinoxan 
would alleviate medetomidine-induced bradycardia in healthy research and client-owned 
dogs without alleviating the desired central effects (Study I and III) as demonstrated earlier 
in dogs and many other species, and that vatinoxan would show high peripheral selectivity 
in dogs (Study II), as previously demonstrated in marmosets and rats (Clineschmidt et al. 
1988). An additional, hypothesis was that the accelerated IM absorption of concomitantly 
given drugs caused by vatinoxan might quicken the onset and conversely, shorten the 




2 REVIEW OF THE LITERATURE  
2.1 Background of receptor agonism and antagonism 
The role of receptors as the target of drug action has guided the understanding of drug 
action and drug discovery since the beginning of 20th century (Langley 1901, 1905). Langley 
(1905) described a receptive substance (acetylcholine) of a skeletal muscle that was 
responsible for a cascade (binding at the postsynaptic membrane of the neuromuscular 
junction) that resulted in a physiological response (skeletal muscle contraction). The concept 
of drug agonism and antagonism was described by Gaddum (1937), who introduced a model 
of a competitive receptor binding of two ligands. In the past 60 years, the current 
understanding of receptors has been built on by the work of multiple pharmacologists (Rang 
2006).  
The structure of the ligand, a substance that forms a complex with a biomolecule, 
determines whether it works as an agonist or antagonist at a receptor (Matsui et al. 1989, 
Khan et al. 1999). To be able to bind a ligand, a receptor must have a stereoscopic 
counterbalancing structure within it that matches the ligand (Matsui et al. 1989). As 
postulated by receptor theory, a receptor must possess structural and steric specificity, and 
the receptors have to be finite in number and saturable. Additionally, a receptor must have 
a high affinity for its endogenous ligand at physiological concentrations, and the binding of 
the endogenous ligand should lead to a recognizable chemical event in the body (Rang 
2006).  
An agonist is a molecule that binds to receptor, resulting into an activation of that specific 
receptor. This activation produces a biological response. An antagonist, on the other hand, 
blocks the agonist from activating the receptor. Where a full agonist will always generate a 
maximal response in the receptor, a partial agonist generates a submaximal response. 
Some partial agonists, such as buprenorphine for µ-opioid receptors (Dum & Herz 1981), 
have a high affinity for the receptor and therefore can act as an antagonist in the presence 
of a full agonist, as the partial agonist can prevent full agonist-receptor bonding.  
An antagonist, as opposed to an agonist, produces no recognizable events in the receptor, 
but prevents other ligands from binding to the receptor (Colquhoun 1973). If two agonists 
bind to the same receptor, they can be antagonised by the same antagonist. Competitive 
antagonism can be either reversible or irreversible. Reversible antagonism can be 
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overridden with increased agonist doses, whereas irreversible antagonism cannot be 
overridden when high doses of agonist are present. A drug can also work as a ligand at 
multiple receptors, and therefore act as an agonist and antagonist simultaneously: for an 
example, butorphanol is both a µ-antagonist and ĸ-agonist, as it has affinity for both µ- and 
ĸ- opioid receptors (Commiskey et al. 2005). 
To simplify the relationships, if the efficacy of a full agonist is equal to 1, an antagonist should 
be perceived as 0, and a partial antagonist valued between 0 and 1 (Ross 1996). The α2-
adrenoceptor agonists (such as dexmedetomidine) used in veterinary medicine are 
selective, potent agonists for α2-adrenoceptors both in the central and peripheral nervous 
system (Doze et al. 1989, Maze & Fujinaga 2000) whereas atipamezole is a highly selective 
α2-adrenoceptor antagonist (Virtanen et al. 1989). 
2.2 α-adrenoceptors 
Initially, adrenoceptors were divided into two main classes: α and β (Ahlquist 1948). 
However, currently, α-adrenoceptors are divided into two main groups (α1 and α2) and each 
is further divided into three subtypes. α1-subtypes (α1A, α1B, α1D) and α2-subtypes (α2A, α2B, 
α2C) (Bylund 1988, Bylund et al 1994). α-adrenoceptors consist of a long chain of amino 
acids, that form both hydrophilic and hydrophobic areas, traversing  the cell membrane in 
total seven times. These seven hydrophobic segments consist of 20-25 amino acids (Matsui 
et al. 1989).  
Adrenoceptors are a part of the autonomic nervous system and the endogenous ligands for 
these receptors are catecholamines, such as noradrenaline. Adrenoceptors are G-protein-
linked cell membrane receptors that are distributed within the CNS and peripheral tissues 
(Gilman 1987). They are excitable proteins which selectively react to both endogenous 
hormones and externally given chemicals to initiate a cascade resulting in a physiological 
effect (Matsui et al. 1989, Khan et al. 1999).  
α2A-adrenoceptors mediate sedation and antinociception (Hunter et al. 1997, Lakhlani et al. 
1997, Stone et al. 1997) as well as anesthetic-sparing effects (Lakhlani et al. 1997). The 
locus coeruleus is the largest noradrenergic cell group in the brain and located bilaterally in 
the upper brain stem. It participates in regulating wakefulness or consciousness and is the 
most important site for the hypnotic effects of α2-adrenoceptor agonists (Scheinin & Schwinn 
1992). In general, presynaptic α2-adrenoceptors, which are primarily of the α2A-subtype 
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(Brede et al. 2003), modulate neurotransmitter release, such as noradrenaline, from nerve 
endings via negative feedback mechanism (Langer 1974, Ruffolo 1985) (Figure 1). Current 
α2-adrenoceptor agonists used in veterinary medicine for provision of sedation are not 
selective to any specific α2-subtypes. 
 
 
Figure 1. Presynaptic effect of α2-receptors on the CNS. Most of the presynaptic α2-
receptors are located in the locus coeruleus. The endogenous ligand noradrenaline 
and exogenous α2-adrenoceptor agonists, such as dexmedetomidine, affect the same 
receptors. 
The location of the adrenoceptors within the sympathetic nerve supply, has functional 
significance. α-adrenoceptors mediate almost exclusively the effects of the sympathetic 
portion of the autonomic nervous system peripherally. Adrenoceptors are activated by 
neurotransmitters released from the terminal of the sympathetic nerves or they can be 
stimulated by catecholamines circulating in the body (Guimaraes & Moura, 2001). Hence, 
extra-junctional α-adrenoceptors are stimulated by circulating adrenaline and noradrenaline 
secreted from the adrenal medulla (Langer et al. 1981). 
Post-synaptic receptors that are located on the effector organ tissues or vessels and are 
usually of the α1-subtype. Post-synaptic receptors that are immediately associated with the 
sympathetic nerve varicosity are called junctional receptors, whereas postsynaptic receptors 
without direct innervation, are called extra-junctional receptors (Ruffolo, 1985).  
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The biological effects of adrenoceptors may differ depending on their location, for example 
on nerves, blood vessels or parenchyma of various tissues (Ruffolo 1985, Guimaraes & 
Moura, 2001, Koshimizu et al. 2002). Furthermore, if there is more than one receptor 
subtype present in the same tissue, the effect of an agonist on the receptor is dependent on 
the relative prevalence of the different receptor populations (Guimaraes & Moura, 2001). 
The response in the end-organ is always dependent on the interactions of the α-
adrenoceptors and catecholamines that are released from the adrenal gland and the 
sympathetic nerve endings (Bennett et al. 1998). Most of the sympathetic functions are 
controlled by α-adrenoceptors that are located near a sympathetic synapse, whereas 
receptors that lack innervation have an additional role. (Brede et al. 2003). 
Smooth muscle in the vasculature, with the exception of pre-capillary sphincters, has broad 
α-adrenergic innervation (Pang 2001, Chiba & Yang 2003). The tone of the sympathetic 
nervous system is responsible for maintaining partial vascular smooth muscle contraction 
(Long & Kirby 2008). Both α1- and α2-adrenoceptors regulate vasomotor tone (Piascik et al. 
1990). In genetically altered mice, α2B-subtype is mainly responsible for mediating arterial 
vasoconstriction. Nevertheless, also α2A- and α2C-adrenoceptors mediate the 
vasoconstriction of smaller arteries (Chotani et al. 2004). Postsynaptic receptors that 
regulate basal vasomotor tone are mainly α1-adrenoceptors, which are activated by the 
catecholamines released from adrenal medulla or from the sympathetic nerve endings 
(Langer et al. 1981, Ruffolo 1985, Docherty 2010). In general, α1-adrenoceptors are 
junctional and are primarily responsible for vasoconstriction (Tanoue et al. 2003) since they 
stimulate the contraction of smooth muscle within the wall of arteries and arterioles 
(Guimaraes & Moura, 2001). α1-adrenoceptors are located to receive direct messages from 
the vasomotor centre in the CNS, and therefore are the primary effectors of changes in 
centrally mediated sympathetic tone (Guimaraes & Moura, 2001). Peripheral α2-
adrenoceptors, that are typically extra-junctional (Yamaguchi & Kopin 1980, Langer et al. 
1981), have a lesser role in systemic arterial vasoconstriction compared to α1-receptors 
(Leech & Faber 1996), but regulate the vasoconstriction of smaller peripheral arteries 
(Chotani et al. 2004).  
Venous vasculature also has extensive sympathetic innervation. Post-synaptic α1- and α2-
adrenoceptors mediate the constriction of venous smooth muscle (Pang 2001). On the 
contrary to arterial circulation, venous α2-adrenoceptors are predominantly junctional and 
α1-adrenoceptors are primarily extra-junctional (Guimaraes & Moura, 2001). Therefore, the 
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most important receptor responsible for the regulation of the venoconstriction is the α2-
adrenoceptor. In the dog the cutaneous or splanchnic venous circulation have particularly 
dense α2-receptor populations (Flavahan & Vanhoutte 1986, Guimaraes et al. 1987). 
 
α2-adrenoceptors take part in mediation of multiple functions in the body. α2A-adrenoceptors 
have an important role on for an example glucose homeostasis and regulation of insulin 
secretion (Peterhoff et al. 2003, Fagerholm et al. 2004, 2008, Savontaus et al. 2008) as well 
as platelet aggregation (Scheinin & MacDonald 1989). α2A-adrenoceptors receptors are 
responsible for mediating hypothermia (Hunter et al. 1996), hypotension and bradycardia 
(MacMillan et al. 1996, Altman et al 1999). Some of the physiological effects of different α2-
adrenoceptor subtypes are listed in Table 1. 
 
 
Table 1. Some physiological effects mediated by α2-adrenoceptor subtypes 
Receptor 
subtype 
Physiological response Anatomical location References 




Altman et al. 1999, 
MacMillan et al. 1996 
Spinal antinociception Spinal cord Stone et al. 1997 
Sedation  Cerebral cortex 
Locus coeruleus 
Hunter et al. 1997, 
Lakhalani et al. 1997 
Aggregation Platelets (Scheinin & 
MacDonald 1989) 
Arterial vasoconstriction Arterial walls MacMillan et al. 1996 
Thermoregulation Hypothalamus Hunter et al. 1997 
Glucose homeostasis, 
regulation of insulin 
secretion 
Pancreatic β-cells Peterhoff et al. 2003, 
Fagerholm et al. 
2004, 2008, 
Savontaus et al. 2008 
α2B 
 
Vasoconstriction Vascular smooth 
muscle 
Link et al. 1996, 
Makaritsis et al. 1999 
α2C 
 
Spinal antinociception Spinal cord (dorsal 
root ganglia) 
Fairbanks et al. 2002 
Thermoregulation Hypothalamus Sallinen et al. 1997 
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In summary, as composed in the α-adrenoceptor review by Giovanniitti (2015) α1-
adrenoceptors are responsible for constriction of vascular smooth muscle, radial muscle of 
the eye and smooth muscle of the vas deferens. α2-adrenoceptors, on the other hand, are 
responsible for centrally induced sedation via locus coeruleus and inhibition of 
norepinephrine release from presynaptic neurons. Additionally, α2-adrenoceptors mediate 
centrally mediated pain modification through the dorsal horn and inhibition of insulin release 
(GIovanniitti et al 2015).  
 
2.3 α2-adrenoceptor agonists  
α2-adrenoceptor agonists are widely used in veterinary medicine for their sedative, analgesic 
and anxiolytic effects. This group of drugs has been in use in the veterinary field since the 
1960s when xylazine was introduced for horses and cattle (Clarke and Hall, 1969). Later on, 
more novel drugs with a higher selectivity towards α2-adrenoceptors have been developed. 
Nowadays multiple α2-adrenoceptor agonists are available for veterinary use, such as 
xylazine, romifidine, clonidine, detomidine, medetomidine and dexmedetomidine. In small 
animal medicine, medetomidine and dexmedetomidine are currently the most frequently 
used α2-adrenoceptor agonists, due to their greater affinity for α2-adrenoceptors (α2:α1-ratio 
of 1620:1 with medetomidine, compared to α2:α1-ratio of 160:1 for xylazine) (Virtanen et al. 
1988).  
Sedative effects of α2-adrenoceptor agonists result from inhibition of noradrenaline release 
from noradrenergic receptors. These receptors are located in the nucleus locus coerulus, 
and they are thought to be responsible for the controlling the sedative as well as 
antinociceptive effects of α2-adrenoceptor agonists (Scheinin and Schwinn, 1992).  
However, all α2-adrenoceptor agonists have adverse effects mainly related to depression of 
the cardiovascular system. They induce vasoconstriction mediated via post-synaptic α2-
receptors located in vascular smooth muscle (Bloor et al. 1992, Flacke et al. 1993, 
Pypendop & Verstegen, 1998). Higher systemic vascular resistance occurs in this phase. 
Bradycardia is attributed partly to a reflex elevation on vagal tone because baroreceptors 
are stimulated by the elevated blood pressure, and persists after the hypertensive phase 
resulting in reduced cardiac output (Thurmon et al 1994: Sinclair et al 2003) and oxygen 
delivery (Doxey et al 1981, Savola 1989, Bloor et al 1992, Pypendop et al 1998). 
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In addition to central and cardiovascular effects, α2-adrenoceptor agonists have vast effects 
on other body functions. Medetomidine inhibits insulin secretion resulting in hyperglycemia 
and increases growth hormone secretion. Additionally, it increases diuresis and reduces 
plasma concentrations of catecholamines similarly to other α2-adrenoceptor agonists 
(Schenin et al. 1987).  
2.3.1  Medetomidine and dexmedetomidine 
Medetomidine (International Union of Pure and Applied Chemistry  name [(RS)-4-[1-(2,3-
dimethylphenyl)ethyl]-3H-imidazole] is a racemic mixture of two enantiomers, 
dexmedetomidine [(+)-4-[1-(2,3-dimethylphenyl)ethyl]-1H-imidazole] and levomedetomidine 
[(-)-4-[1-(2,3-dimethylphenyl)ethyl]-1H-imidazole]. Dexmedetomidine is the active 
component, whereas levomedetomidine is considered pharmacologically inactive 
(MacDonald et al. 1991, Kuusela et al. 2000, 2001). In canine plasma, medetomidine is 
bound to protein up to 85% (Salonen 1989). The elimination half-life was approximately 60 
minutes after intravenous administration in dogs, whereas clearance was 1.3-1.8 l/kg/h 
(Salonen 1989, Kuusela et al. 2000).  
(Dex)medetomidine is widely used in small animal veterinary medicine. It is a selective and 
efficacious agonist at α2-adrenoceptors both in the central and peripheral nervous system 
(Doze et al. 1989, Maze & Fujinaga 2000) that produces sedation, muscle relaxation and 
antinociception in dogs (Vainio et al. 1989, Salonen et al. 1992, Grimm et al. 2000, Kuusela 
et al. 2001, van Oostrom et al. 2011). Dexmedetomidine induces dose-dependent sedation 
by decreasing the activity of noradrenergic receptors within the CNS (Rabin et al. 1996, 
Millan et al. 2000, Lähdesmäki et al. 2003). (Dex)medetomidine induces the depressant 
effects on the cardiovascular system typical of all α2-adrenoceptor agonists, such as 
bradycardia, increased systemic vascular resistance, and decrease in oxygen delivery, as 
described earlier in the review.  
Dexmedetomidine is commonly used as a part of an anaesthetic regimen because its 
administration potentiates the effects of other hypnotic and sedatives agents (Salonen 1989, 
Scheinin et al. 1993, Ben-Abraham et al. 2000, Kuusela et al. 2001). When used as a 
preanesthetic, dexmedetomidine decreases the minimum alveolar concentration (MAC) of 
halothane (Vickery et al. 1988, Bloor et al. 1992), isoflurane (Pascoe et al. 2006) and 
sevoflurane (Hector et al. 2017). 
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2.4 α2-adrenoceptor antagonists 
Reversal of the sedation caused by α2-adrenoceptor agonists is often required for practical 
reasons after sedation of animals. α2-adrenoceptor antagonists, such as yohimbine, 
tolazoline and atipamezole, can be used as reversal agents. Yohimbine, a compound that 
was extracted from a bark of a tree over 100 years ago, was the first α2-adrenoceptor 
antagonist used in the field of veterinary medicine.  
As described with α2-adrenoceptor agonists earlier, similar development towards more 
selective α2-adrenoceptor antagonists has been seen. Respectively, atipamezole has a 
α2:α1- selectivity ratio of 8526:1 compared to 40:1 to yohimbine and 27:1 to idanoxan 
(Virtanen et al. 1989).  
2.4.1 Atipamezole 
Atipamezole is a potent α2-adrenoceptor antagonist that is widely used in veterinary 
medicine for reversal of both sedative and analgesic effects of α2-adrenoceptor agonists. It 
affects both centrally and peripherally located α2-receptors (Virtanen et al. 1989). It reverses 
the centrally-mediated effects of dexmedetomidine (Clarke & England 1989, Vainio 1990, 
Vähä-Vahe 1990, Granholm et al. 2007).  
In addition to blocking of the central effects of α2-adrenoceptor agonists, such as sedation, 
atipamezole has an effect on peripheral α2-adrenoceptors (Virtanen et al. 1989), leading to 
the reversal of medetomidine-induced bradycardia (Vähä-Vahe 1990). However, transient 
hypotension may be seen, probably due to vasodilation (Vainio 1990). When higher 
atipamezole doses are used, greater increases in heart rate (HR) are observed (Vähä-Vahe 
1990), but hypotension may also be detected (Vainio 1990). Atipamezole doses that were 
five or ten times the preceding dose of medetomidine (20, 40 or 80 µg/kg of medetomidine 
IM) given 30 minutes after medetomidine, significantly increased HR in dogs from 40-46 
beats per minute to 67-95 beats per minute within 10 minutes. Additionally, mean arterial 
pressure (MAP) decreased within 3 minutes after atipamezole administration (Vainio 1990).  
In dogs treated with medetomidine and vatinoxan, atipamezole can be used to reverse the 
sedative effects of medetomidine in the presence of vatinoxan without adverse 
cardiovascular effects. Atipamezole failed to increase cardiac index in dogs given 
medetomidine, while vatinoxan enhanced haemodynamic function (Turunen et al. 2019).  
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Atipamezole alters the elimination of medetomidine, as the administration of atipamezole 
intramuscularly reduces the area under curve (AUC) of medetomidine in medetomidine-
sedated dogs (Salonen et al. 1995). Atipamezole, as well as medetomidine are metabolized 
in the liver through hydroxylation, but no metabolic interaction between these two drugs has 
been detected (Salonen et al. 1995). However, increased clearance of medetomidine in the 
presence of atipamezole has been thought to be a result from the restoration of 
hemodynamic function after atipamezole administration (Baratta et al. 2009). 
2.4.2 Vatinoxan 
Vatinoxan is a selective (α2:α1-ratio 105:1) peripheral α2-adrenoceptor antagonist that poorly 
penetrates the BBB (Clineschmidt et al. 1988). Brain/plasma concentration ratios of 0.02 for 
marmosets and 0.05-0.09 for rats for vatinoxan have been reported. This finding has been 
speculated to result from the relatively low lipid solubility of vatinoxan (Clineschmidt et al. 
1988). Hence, the α2-agonist-induced sedation is not markedly decreased by vatinoxan, as 
demonstrated in dogs (Pagel et al. 1998, Enouri et al. 2008, Honkavaara et al. 2008, 
Restitutti et al. 2011) whereas the negative peripheral effects, such as hypertension and 
bradycardia, have been alleviated with both IV and IM administration of vatinoxan in this 
species (Pagel et al. 1998, Honkavaara et al. 2011, Rolfe et al. 2012, Restitutti et al. 2017). 
Elimination half-life for vatinoxan is approximately 40 minutes and clearance is 7.8 ± 3.4 
ml/kg/minute in dogs (Honkavaara et al. 2012).  
Generally, attenuation of the initial vasoconstriction is considered to be desirable because it 
alleviates the baroreflex-mediated bradycardia (Pypendop et al. 1998). Conversely, when 
the α2-adrenoceptor agonist-induced vasoconstriction is ameliorated, the risk for 
hypotension increases. It was demonstrated in isoflurane-anaesthetized dogs that 
preoperative administration of medetomidine and vatinoxan provided cardiovascular stability 
during both the preanesthetic and perioperative period. While the effect of a medetomidine 
and vatinoxan combination on blood pressure was comparable to that produced by 
acepromazine-butorphanol when these drugs were used for premedication (Salla et al. 
2014a). Acepromazine decreases arterial blood pressure through vasodilation mediated via 
α1-adrenoceptors blockade (Ludders et al. 1983, Monteiro et al. 2007). 
The clinically optimal dexmedetomidine:vatinoxan dose ratio seems to be dependent on the 
species and route of administration. In dogs, dexmedetomidine:vatinoxan ratios between 
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1:20-1:80 prevented the immediate cardiovascular effects of dexmedetomidine when 
vatinoxan was administered prior to IV dexmedetomidine (Pagel et al. 1998). Additionally, 
Honkavaara et al. (2011) reported that a dexmedetomidine:vatinoxan dose ratio of 1:50  
(using dose ratios of 1:25, 1:50 or 1:75) seemed most appropriate for dogs when used IV in 
the same syringe. Restitutti et al. (2017) administered vatinoxan IM at three dose ratios 
concomitantly with medetomidine (corresponding dexmedetomidine:vatinoxan ratios of 
1:20, 1:40 and 1:60), and initially with all three doses, the cardiovascular effects of 
medetomidine, such as decreased HR and cardiac output (CO), were demonstrated. 
However, with the two higher doses of vatinoxan, MAP transiently increased and then 
significantly decreased from the baseline (Restitutti et al. 2017).  
 
2.5 Principles of drug absorption, distribution, metabolism 
and excretion (ADME) 
 
There are multiple routes for drug administration, such as IM, IV, gastrointestinal, 
percutaneous, respiratory, and subcutaneous. In this thesis, the IM route is studied. The 
distribution of drugs, particularly vatinoxan, into the CNS is emphasized. Distribution to 
peripheral tissues depends on the physiochemical properties of the molecule, concentration 
gradient between the blood and tissue, the blood flow to the tissue and the affinity of the 
drug molecule for different tissue components. Since this thesis focuses on the absorption 
and distribution phases, the details of drug metabolism and elimination are not described. 
 
2.5.1 Absorption 
In order to move in order to enter and exit cells, drugs as well as other molecules must cross 
semipermeable lipid-based membranes. Lipid-soluble, nonpolar molecules are able to 
readily pass these membrane barriers. Additionally, membranes are more permeable to the 
nonionized forms of weak organic acids and bases. The degree of ionization (pKa) defines 
what proportion of a drug is present in its nonionized form at a given pH. Briefly, lipid-soluble 
drugs are readily absorbed into the body, whereas hydrophilic drugs are absorbed more 
slowly (Becker & Reed 2012). 
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2.5.1.1 Intramuscular absorption 
In addition to a drug’s physical properties, absorption can be influenced by the physiological 
state of the animal, the administration site and certain chemical factors, such as 
inflammatory mediators. The physiological state of the animal can affect the absorption 
through vascular tone. Vasodilation increases, while, vasoconstriction delays the IM 
absorption. One way to either delay or increase the absorption phase is to alter the vascular 
tone of blood vessels at the injection site. Vasopressors added to local anaesthetic 
formulations prolong the absorption phase by causing vasoconstriction. For example, 
adrenaline is added to local anaesthetic solutions for this purpose (Becker & Reed 2012). 
The absorption of drug molecules into a tissue also depends on capillary density and the 
mass of the target tissue. 
The IM route of administration has been widely used and studied in veterinary medicine due 
to its convenience during clinical work. This route is also used when it is not possible to 
obtain IV access without causing excessive stress and discomfort. In humans, the IM route 
is used when the IV route is not a viable option due to the low aqueous solubility of a drug 
or if the high peak concentrations after IV administration might cause unwanted effects 
(Zuidema et al. 1988).  
Drug release after IM administration is affected by the molecular mass of the drug, its pKa, 
co-solvents, a drug’s water solubility and concentration, the depth of  injection, muscle 
activity, blood supply at the injection site and body movement (Zuidema et al. 1988). 
Additionally, binding of the drug to the tissue plays an important role in the absorption phase 
(Sund & Schou 1964). One possible factor causing variation in IM absorption is the 
temperature of the injected solution. Administration of azaperone and ketamine to pigs, at 
temperatures of 7, 20 and 39°C, showed that animals became recumbent more rapidly 
following injection of the two warmer mixtures. Warmer injectates are believed to dilate the 
diameter of blood vessels in the muscle, leading to a more rapid absorption of the drugs 
(Clutton et al. 1998).  
The activity and blood flow to a muscle (Self et al. 2009, Benet et al. 2011), perimuscular fat 
and intermuscular fascial planes (Sund & Schou 1964, Baxter & Evans 1973) affect the 
bioavailability of the drug. The rate absorption of drug molecules from the adipose tissue is 
slower than that from the muscle tissue, owing to the poor blood flow in the former tissue 
(Dundee et al. 1974, Pieters & Zuidema 1986). Resting muscle blood flow varies between 
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specific muscle groups, for example the magnitude of blood flow in the gluteus maximus, 
vastus lateralis, and deltoid muscles differs to such a degree that it   affects the rate of drug 
absorption. These differing rates of absorption also affect drug plasma concentrations after 
IM administration of drugs, as reported in humans (Evans 1975). Furthermore, at rest, 
postural muscles, have a larger blood supply when compared to non-postural muscles 
(Benet et al. 2011). Conversely, the influence of decreased muscle perfusion on absorption 
rate was demonstrated in humans administered IM injections of the hydrophilic antibiotic, 
gentamicin, after spinal cord injury. The reported drug absorption rate was lower in 
paralyzed muscle compared to non-paralyzed muscle probably due to reduced muscle blood 
flow, whereas volume of distribution (Vd) and clearance (CL) were increased (Segal et al. 
1988). Whether injection is IM or intermuscular, defined as injection within the muscle or 
between the muscle fascias respectively, also affects the rate of drug absorption (Groothuis 
et al. 1980).  
 
2.5.2 Distribution 
After a drug molecule has been absorbed, it has to reach its site of action at a sufficient 
concentration to elicit a biological response. Distribution is the process by which the drug 
molecules are transported to tissue by the circulation. Passive transport of a drug is 
dependent on four main factors: (i) the properties of the drug (most importantly lipid 
solubility, molecular weight and pKa as described earlier); (ii) the concentration gradient 
between blood and tissue; (iii) the ratio of blood flow to tissue mass and, (iv) the affinity of 
the drug to tissue constituents.   
Both importation and exportation of drugs to and from cells by active transporters is 
adenosine triphosphate (ATP)-dependent, thus requiring energy (Al-Shawi & Senior 1993). 
Crone et al. (1965) demonstrated carrier-mediated transport of a solute across the BBB for 
the first time with dextrose. The distribution of drugs is mediated by efflux and influx drug 
transporters. Additionally, the protein binding of drug molecules influence distribution since 
only free drug molecules can penetrate tissue membranes.  
The body fluids are divided into three major compartments: intravascular, interstitial and 
intracellular fluid. After IM injection, whether a molecule distributes only into the blood or all 
three compartments, affects its concentration. A molecule that distributes only into plasma 
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achieves higher concentrations in plasma than a molecule that distributes into interstitial and 
intracellular fluid as well. Additionally, the blood flow within the tissue affects the distribution; 
high blood flow per unit mass of tissue as well as large tissue mass contribute to chemical 
accumulation of drug molecules into that tissue. Brain, heart, kidney, liver and endocrine 
glands are tissues with high blood flow. Muscles and skin have intermediate blood flow per 
tissue mass whereas adipose tissue and bones have low blood flow. 
Binding to plasma proteins is one of the factors influencing drug disposition. The most 
important binding proteins in the serum are albumin and α1-acid glycoprotein (Bohnert & 
Gan 2013). When a molecule binds to plasma protein, this newly-bound complex travels 
through the circulation until it dissociates. Usually this happens when the affinity of the drug 
for another molecule, such as a transporter protein, or tissue component is greater than that 
for the plasma protein. The effect of the drug in the body is usually dependent upon the 
unbound concentration of drug in the plasma. Therefore, changes in the concentration of 
plasma proteins may change the amount of the unbound drug in the circulation. Additionally, 
co-administered drugs may lead to competition of the same binding sites in plasma proteins 
(Israili & Dayton 2001).  
 
2.5.2.1 BBB and blood-spinal cord barrier (BSCB) 
The BBB is a protective mechanism that forms a lipophilic, semipermeable interface 
between the brain parenchyma and the blood stream. It mediates the entry of nutrients, ions 
and other molecules to brain parenchyma, whilst, protecting the brain from xenobiotics e.g. 
toxins, and pathogens (Daneman 2015).  
The BBB is comprised of brain microvascular endothelial cells that form the walls of the 
capillaries, astrocytes, pericytes and the basement membrane (Figure 2) (Zlokovic 2008, He 
Y et al. 2014, Yao et al. 2014). Beneath the endothelial and epithelial cells in the brain, lies 
the basement membrane (Hynes et al. 2009, Baeten et al. 2011, Kim et al. 2011), a 50-100 
nm thick protein sheath (Vracko 1970, Ruben 1994) that surrounds the endothelial cells and 
pericytes (Engelhardt & Sorokin 2009). Basement membrane has many important functions, 
such as: structural support; signalling transduction and cell anchoring (Hynes et al. 2009, 
Kim et al. 2011, Baeten et al. 2011). Pericytes are a type of mesenchymal cell that are 
embedded in the basement membrane and located in the perivascular space, between the 
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capillary wall and astrocytic end-feet. Pericytes probably play a critical role in the synthesis 
of the basement membrane components, such as proteoglycans, but their contribution to 
the system is poorly understood. The basement membrane seems to be maintained by all 
the cells of the BBB: endothelial cells; pericytes and astrocytes (Engelhardt & Sorokin 2009, 
Cardoso et al. 2010).  
Astrocytes form part of the BBB and they are essential for the development, maintenance 
and function of this barrier. (Bauer & Bauer 2000, Abbot 2006, Engelhardt & Sorokin 2009, 
Cardoso et al. 2010). More than contributing to the physical properties of the BBB, 
astrocytes modulate the BBB via secretory mechanisms that in turn establish the properties 
of cellular components (Bauer & Bauer 2000, Abbot 2006, Engelhardt & Sorokin 2009, 
Cardoso et al. 2010). 
 
 
Figure 2. The anatomical structure of the BBB. 
 
The BSCB is a morphologically similar structure to the BBB (Bartanusz et al. 2011). 
Compared to the BBB, the BSCB is more permeable to, for example cytokines, and regional 
differences in the permeability of the spinal cord to cytokines have been detected (Pan et 
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al. 1997). Ge & Pachter (2006) studied cultured microvascular endothelial cells from the 
murine spinal cord and demonstrated decreased expression of tight junction-associated 
proteins in spinal cord when compared to brain endothelial cells. However, the expression 
of some tight junction-associated proteins remained unchanged (Ge & Pachter 2006). These 
findings may explain the differences in the permeability of BSCB and the BBB to some drugs 
(Pan et al. 1997). 
 
2.5.2.2 Transport through the BBB 
In order to penetrate the BBB and thereby gain access to brain tissue, a molecule has to 
pass through two membranes of the endothelial cells in the BBB. Three important factors 
modulating and controlling drug disposition in the CNS are passive membrane permeability, 
active transport through the BBB and the degree of tissue binding between the brain and 
plasma compartments (Jeffrey & Summerfield 2010).  
Physiological tissue barriers, such as the BBB or BSCB, affect the distribution of drug 
molecules. If a molecule is unable to pass through these tissue layers on its own, for 
example owing to its size or low lipid solubility, it needs assistance from active transporter 
proteins. Transportation through the BBB includes both uptake mechanisms and efflux 
transporters. In addition to these mechanisms, astrocytes and other cells can release 
chemical factors modulating the permeability of the endothelial cells very quickly, over 
seconds to minutes (Abbott, 2002). 
Tight junctions between endothelial cells limit the movement of hydrophilic molecules 
through the BBB, while, small lipophilic substances, such as oxygen and carbon dioxide, 
diffuse freely according to their partial pressure gradients (Grieb et al. 1985). There is a 
strong association between the penetration of drugs into BBB and their lipophilicity 
(Rapoport 1976, Pardridge 1981). For example, the α2-adrenoceptor agonists used as 
sedatives are lipid soluble molecules that have a low molecular weight (< 400 Da) and 
therefore are able to cross the BBB (Salonen 1989).   
Protein-transporters are located within the cell membrane and by virtue of their location they 
effectively mediate the pharmacological characteristics of many clinically used drugs 
(Fromm, 2000, Ayrton & Morgan, 2001, Borst & Elferink, 2002, Schinkel & Jonker, 2003, 
Fromm 2004). Peptide receptors of the BBB regulate various processes, such as 
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transcytosis of a ligand from the blood into the brain or from brain to blood (Pardridge 1986, 
2012). There are over 400 membrane transporters that belong to two superfamilies – ATP-
binding cassette (ABC) and solute carriers (SLC) (Schinkel & Jonker 2003, Hediger et al. 
2004, Giacomini & Sugiyama 2006). The process of ABC-transporters requires ATP 
hydrolysis for these efflux transporters to be able to export molecules (Dallas et al. 2006). 
Organic cation transporters (OCTs) and organic anion transporters (OATs) belong to the 
SLC superfamily (Hediger et al. 2004, Koepsell et al. 2007). They transport hydrophilic, 
organic substrates with low molecular mass (typically less than 400 Da) (Ahlin et al. 2008). 
The dog has 52 genes responsible for encoding ABC proteins (Dean & Annilo 2005). These 
proteins are grouped into seven families from ABCA to ABCG (Hediger et al. 2004). ABC-
transporters, such as the breast cancer resistance protein (BCRP, ABCG2), extrude 
endogenous and exogenous substrates across membranes; they protect cells from potential 
toxins by transporting substrate drugs from the cytoplasm out of the cell (Vlaming et al. 
2009). P-glycoprotein is an efflux transporter coded by the ABCB1 gene, formerly known as 
the multi drug resistance gene (MDR1) (Ueda et al. 1987). P-glycoprotein is the best known 
ABC transporter in veterinary medicine, first reported in mdr1a(-/-) knockout mice (Schinkel 
et al. 1994, 1995). In addition to the BBB and BSCB, P-glycoprotein (P-gp) can be found in 
epithelial cells in kidney, liver, testicles, placenta, lungs and intestine. In addition, it is 
expressed in neoplastic cells (Litman et al. 2001, Leslie et al. 2005, Cartwright et al. 2012).  
The human breast cancer resistance protein (ABCG2, BCRP) is another of the better known 
ABC transporters within the BBB (Begley 2004, Daunchy et al. 2008, Kamiie et al. 2008, 
Miller 2010). It limits the bioavailability of some substrates (van Herwaarden & Schinkel, 
2006, Vlaming et al. 2009, Mealey et al. 2011). In addition to previously mentioned 
transporters, multiple additional transporters take part in the active passage of drugs through 
the BBB.  
 
2.5.2.3 What affects the permeability of the BBB? 
Whereas lipid-soluble molecules diffuse through the BBB (Liu et al. 2004) described before, 
high polar surface area and the tendency to form hydrogen bonds restrict the drug molecules 
from accessing the CNS since these characteristics delay the movement of molecules from 
aqueous phase into the lipid cell membrane (Clark 2003).  
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Clineschmidt et al. (1988) speculated that the most probable causes for the low 
concentration of vatinoxan found in the rat brain tissue were its low fat solubility, relatively 
large molecular size and the barrier functions of the BBB. The octanol-water partition 
coefficient, defined as the ratio of a chemical’s concentration in the octanol phase to its 
concentration in the aqueous phase in a two-phase octanol/buffer system, describes the 
behaviour of a molecule in these two phases (Miller et al. 1985). However, the octanol-buffer 
distribution coefficient is 1.27 for morphine (Plummer et al. 1990) which is very similar to the 
1.3 for vatinoxan (Clineschmidt et al. 1988). Therefore, as morphine is known to penetrate 
CNS, the lipophilicity of vatinoxan is probably not sufficiently low to explain its poor 
penetration into the CNS. 
The molecular weight of a drug affects its permeability through the BBB; the molecular 
weight of medetomidine is 200 g/mol (Pubchem), whereas that of vatinoxan is 419 g/mol 
(Pubchem). Although the cut off value for significant molecule passage through the BBB 
cannot be stated definitively, it is between 400 and 657 g/mol (Levin et al. 1980), suggesting 
that the size of vatinoxan molecule may reduce its permeability.   
Bennett et al. (2017) suggested in an in vitro study using human P-gp that vatinoxan was 
probably not a P-gp substrate within the BBB. However, Bennett et al. (2017) could not rule 
out the possibility that vatinoxan was a substrate for other efflux transporters which, have 
not yet been identified. Furthermore, dexmedetomidine showed no evidence of active 
transport (Bennett et al. 2017). However, the importance of P-gp within the BBB has been 
reported in dogs administered macrocyclic lactones such as ivermectin and loperamide 
(Mealey et al. 2001, 2008). A deletion mutation in the gene coding for canine P-gp may lead 
to increased sensitivity to certain drugs, such as butorphanol, in dogs homozygous for this 
mutation (Wandel et al. 2002, Sartor et al. 2004, Mealey 2006). This is evident as symptoms 
of toxicity with avermectin parasiticides such as ivermectin (Mealey et al. 2001). This 
mutation is seen in for an example herding breeds, such as Collies (Mealey 2001, 2008). 
However, mutations in other transporters and their clinical relevance have not been studied 
as widely as P-gp and therefore they are not described fully by the author nor recognised 
as frequently in the literature. 
Many pathological conditions modulate the permeability of the BBB. Many inflammatory 
mediators increase the diameter of the blood vessels and increase their permeability, 
inducing leakage across the BBB (Abbot 2000), which can lead to brain oedema 
(Stamatovic et al. 2008). Several types of molecules, such as histamine, matrix 
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metalloproteases, cytokines, lipids, free radicals and growth factors can increase 
permeability (Stamatovic et al. 2008).  
In conclusion, the characteristics of the molecule, especially its liposolubility, ionization 
and molecule size affect its capacity to passively cross the BBB. In addition, the disease 
state, especially inflammatory or ischaemic states, affect the BBB itself through 
proinflammatory mediators, thus modulating its permeability. Furthermore, active 
transportation of a drug molecule through the BBB can be modulated by inhibition or 
activation of drug transporters.  
 
2.5.3 Metabolism 
In drug metabolism, a drug is processed via metabolic pathways, usually in the liver, to 
modify its chemical structure. Usually the main purpose of metabolism is to ensure 
elimination by increasing the water solubility of the molecule. Drug metabolism can be 
divided into three phases. In the first phase metabolic enzymes add polar or reactive groups 
to the drug molecule. The four pathways available are oxidation, reduction, hydration and 
hydrolysis. The cytochrome P450 (CYP) superfamily of enzymes have an important role on 
phase I liver metabolism through oxidation (Shapiro & Shear, 2002). In the second phase 
drug molecules are conjugated into a polar compound mainly catalysed by transferase 
enzymes. The conjugated drug molecules may be further modified if needed. Thereafter, 
the metabolites are usually recognised by efflux transporters and moved out of the cells. 
 
2.5.4 Excretion 
Excretion is the process of removal of the drug or its metabolites from the body. The ultimate 
route for elimination is kidney, but drugs and their metabolites can additionally be excreted 
in bile, sweat, saliva, tears, milk and expired air. The degree of ionization and water solubility 
determine how much of the drug is excreted via the renal route. In laboratory beagles, 
vatinoxan ameliorated dexmedetomidine-induced changes in blood flow of the kidney 
detected with contrast-enhanced ultrasound (Restitutti et al. 2013).  
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2.6 Pharmacological drug interactions 
When two or more drugs are administered concomitantly, chemical or pharmacological drug-
drug interactions may develop. A pharmacological drug interaction is described as a change 
in the action of a drug due to concomitant administration of another drug, food or supplement 
(Shapiro & Shear, 2002). The pharmacodynamic drug-drug interactions by receptor 
agonism and antagonism have been described earlier. The most common pharmacokinetic 
drug interactions are the inhibition or activation of enzymes taking part in the metabolism of 
the drugs, or the activation and inhibition of transporter proteins (Shapiro & Shear, 2002).  
While the cardiovascular effects of medetomidine are alleviated, vatinoxan also accelerates 
the IM absorption of medetomidine via a probable improvement in perfusion. 
Simultaneously, vatinoxan deepens the medetomidine-evoked sedation through increased 
plasma drug concentrations when given concomitantly using a single injection, as reported 
in dogs (Restitutti et al. 2017). Similar findings have been later reported also in cats 
(Honkavaara et al. 2017, Pypendop et al. 2017).  
Vatinoxan increased the MAC of sevoflurane in dogs, which was speculated to be related to 
CNS penetration by the drug (Hector et al. 2017). Previously it was speculated that changes 
in the distribution of concomitantly given drugs and improved CO due to vatinoxan 
(Honkavaara et al. 2012) would explain the need for higher doses of co-administered drugs. 
However, Hector et al. (2017) administered vatinoxan alone, so changes in clearance or 
distribution of α2-adrenoceptor agonists did not explain this finding. MAC of volatile 
anaesthetics is regulated through effects at the spinal cord level (Eger et al. 2002), and there 
is proof that the permeability of the BSCB and BBB differs to interferons, for example (Pan 
et al. 1997, Bartanusz et al. 2011). Hence, if vatinoxan penetrates BSCB more easily than 
BBB, this might explain the   higher MAC of volatile anesthetics in the presence of vatinoxan. 
Therefore, the effects of vatinoxan on the MAC of sevoflurane (Hector et al. 2017) might be 
also explained by variation in the permeability of BSCB and the BBB (Pan et al. 1997). 
Changes in cardiovascular performance, for an example through improved CO, might affect 
the distribution of sevoflurane, which could be one factor explaining the findings reported by 
Hector et al. (2017). However, atipamezole has been shown to have no effect on the MAC 
of isoflurane in rats and dogs after the administration of α2-adrenoceptor agonists (Ewing et 
al. 1993, Eger et al. 2003). 
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Inducers or inhibitors of CYP-enzymes can induce or inhibit the metabolism of drugs by 
influencing their clearance. For example, medetomidine is a CYP2B11 inhibitor (Baratta et 
al. 2009), and it may inhibit the clearance of some drugs, such as midazolam and ketamine. 
It has been suggested that this drug-drug interaction is one explanation for the dose-sparing 
effects of medetomidine (Baratta et al. 2009). Drug interactions are possible at the level of 
the BBB, because it is not just a passive anatomical barrier, but also a complex active 
interface expressing a variety of active influx and efflux transporters. The inhibition and 
activation of transporter proteins is an important drug interaction mechanism; whereas 
ketoconazole and omeprazole work as inhibitors of P-gp, rifampicin acts as an inducer for 
P-gp (Solhaug et al. 2019). Molecules can work as both substrates and inhibitors. For a 
clinically relevant example, methadone works as a substrate for cytochromes CYP2B6 and 
CYP3A4/5 as well as P-glycoprotein; however, it works as an inhibitor for the enzyme 
CYP2D6 (Solhaug et al. 2017). In renal cells, clarithromycin decreases secretion of digoxin 
through the inhibition of P-gp in the kidney cells (Wakasugi et al. 1998).   
Drug elimination is also dependent on the perfusion of the organs in question. As 
medetomidine reduces CO (Thurmon et al. 1994, Sinclair et al. 2003), it may delay or 
decrease drug excretion of concomitantly given drugs via the renal route. Atipamezole, on 
the other hand, accelerates the elimination phase of medetomidine; CL increases and T½ 
decreases (Salonen et al. 1995). These changes are supposed to be dependent on the 
restoration of haemodynamic function following the atipamezole administration to dogs 
treated with α2-adrenoceptor agonists. Vatinoxan also increases early disposition of 
dexmedetomidine following an IV bolus administration by doubling the apparent Vz and CL 
of dexmedetomidine (Honkavaara et al. 2012, Bennett et al. 2016). The effect on clearance 
of α2-adrenoceptor agonists is probably mediated via improvement or restoration of 
CO,which enhances hepatic perfusion.  
In conclusion, generally important mechanisms for pharmacological drug-drug interactions 
are the induction or inhibition of drug metabolism through enzymes, inhibition or activation 
of transporter proteins, pharmacodynamic potentiation and drug antagonism, such as 
competitive inhibition. However, particularly α2-adrenoceptor agonists and antagonists may 
also induce pharmacokinetic drug-drug interactions by altering blood circulation.  
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3 AIMS OF THE STUDY 
 
1. To describe the effects vatinoxan on plasma concentrations and especially on 
absorption of medetomidine (MED) and certain other drugs when administered 
concomitantly intramuscularly in healthy dogs (I, III) 
2. To compare the concurrent concentrations of vatinoxan and the enantiomers of 
medetomidine in canine plasma and CNS after intravenous co-administration 
(I, II) 
3. To confirm the effects of vatinoxan on the clinical characteristics of 
medetomidine-butorphanol combination in healthy client-owned dogs sedated 
for routine radiographic imaging. (III) 
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4 MATERIALS AND METHODS 
4.1 Ethical approval 
The National Animal Experimental board provided ethical approval for all of the studies 
(ESAVI/7187/04.10.03/2012, study I), (ESAVI-2010-04178/Ym23, study II) and 
(ESAVI/6082/04.10.07/2016, study III). 
 
4.2 Animals 
The laboratory beagles used in studies I and II were considered healthy based on recent 
clinical and neurological examinations, complete blood counts and serum chemistry. For 
study I, six purpose-bred beagle dogs (four castrated males and two ovariohysterectomized 
females, mean weight ± standard deviation (SD) 14.4 ± 1.6 kg) were used. These beagles 
have now been rehomed and enjoying their life as pets. In study II, six research Beagle dogs 
(four females, two males, mean weight 12.5 ± 1.4 kg) scheduled for euthanasia for reasons 
other than this study (Heikkilä et al. 2018), were used. Beagles used in study I and II were 
housed according to the European Union guidelines (63/2010/EU) in groups in indoor pens 
with access to outdoor runs so that they were exposed to both artificial (from 7:00 to 16:00) 
and natural light. The indoor environmental temperature was between 15 and 24 ºC. Food 
was withheld for 12 hours before each study, water was freely available. 
For the study III, 57 client-owned dogs requiring sedation for non-invasive diagnostic 
imaging purposes were used. The dogs weighed 5 kg or more and were between 3 months 
and 10 years of age.  
 
4.3 Instrumentation 
In all studies, a 20 or 22-gauge intravenous (IV) catheter (Terumo Europe N.V., Belgium) 
was placed either in the cephalic vein (I, III) or lateral saphenous vein (II).  
In study I, a 16 gauge  single lumen central venous catheter (MILA International Inc, KY, 
USA) was inserted aseptically into a jugular vein for blood collection under local anaesthesia 
(5 mg lidocaine subcutaneously, Lidocain 20 mg, Orion Pharma, Finland) and fixed to the 
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adjacent skin with topical tissue adhesive (Gluture, World precision instruments, FL, USA). 
A 3-way stopcock was attached to this catheter to enable blood collection. 
 
4.4 Treatments, drugs and doses 
The study number, treatments and drug doses are listed in Table 2. In study I there was a 
14-day wash-out period between treatments. In study I, random allocation was performed 
drawing lots: three tickets with the word “treatment”, and three tickets with the word “control” 
were drawn in a randomized order. I study III, seven blocks with 4-10 animals were created 
to get an even distribution of sizes and breed types between the treatment groups. 
Randomization was performed within these blocks by using a specific software by a person 
who did not take part in the study otherwise.  
 
Study Number and 
source of 
dogs    





IM 1) medetomidine hydrochloride 20 
µg/kg + butorphanol 100 µg/kg + 
midazolam 200 µg/kg (MBM)  














owned dogs  
IM 1) medetomidine 0.5 mg/m2 + 
butorphanol 0.1 mg/kg (MB)  
2) medetomidine 0.5 mg/m2 + 
vatinoxan 10 mg/m2 + butorphanol 0.1 







In study I, 1 mL of medetomidine solution (1 mg/mL of medetomidine hydrochloride (HCl) 
(Dorbene 1 mg/mL, Vetcare Oy, Finland) and 1 mL of saline solution (Natriumklorid, B. 
Braun, 9 mg/mL) were mixed in an ampoule containing 25 mg of vatinoxan hydrochloride 
powder. For the treatment without vatinoxan, 1 mL of medetomidine hydrochloride solution 
was mixed with 1 mL of saline. The drugsolutions (MBM or MBM-V) were drawn up into 
syringes and mixed with butorphanol (Torpudor 10 mg/mL, Richter Pharma AG, Austria) and 
midazolam (Midazolam Hameln 5 mg/mL, Hameln Pharmaceuticals Gmbh, Germany). The 
solution was confirmed to be colourless, clear, and transparent. Injection was administered 
into lumbar epaxial muscles with the dogs in lateral recumbency. The contralateral sites 
were used for the second treatments.  
In study II, vatinoxan was diluted in a similar manner to study I. A dose of 40 µg/kg 
medetomidine HCl was used (Dorbene 1 mg/mL, Laboratories Syva, , Spain) with   800 
µg/kg of vatinoxan HCl (Vetcare Ltd,, Finland) was administrated as a rapid IV bolus. The 
dogs were euthanized 20 minutes after medetomidine and vatinoxan administration with an 
overdose of IV pentobarbital (140 mg/kg, Euthasol 400 mg/mL, Le Vet BV, Netherlands). 
In study III, dogs were given either treatment MB or MBV. Dosage of medetomidine was 
calculated based on body surface area using the formula: body surface area = 10.1* kg2/3 * 
10-2 (White & Kearney 2014, Pypendop & Jones 2015). The dose of medetomidine was 
equivalent to a dose of 29.5 µg/kg for a 5 kg dog and 11.7 µg/kg for an 80 kg dog. A solution 
of 0.5 mg/mL of medetomidine HCl (vials for experimental use were provided by Vetcare 
Ltd, Finland) was used for MB-treatment, and for MBV, a solution containing 0.5 mg/mL of 
medetomidine HCl and 10 mg/mL of vatinoxan was used. Butorphanol was drawn up into a 
separate syringe but mixed with medetomidine solution in a single syringe before 
administration IM into the gluteal muscles.  
 
4.5 Assessment of sedation 
In studies I and III, the assessment of the level of sedation was performed with both a visual 
analogue scale (VAS; analog scale of 0-100) and a descriptive sedation score (DSS) (Table 
3). VAS and DSS were assessed by the same person, blinded to treatment, before and 3, 
6, 10, 15, 20, 25, 30, 40, 50, 60 and 90 minutes after injection in study I. In study III, sedation 
was assessed at 0, 5, 10 and then at 10 minute intervals after drug administration. 
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Table 3. Descriptive sedation score 
0 = No sedation 
1 = Can stand / walk, but ataxic 
2 = Recumbent, strong resistance to lateral positioning 
4 = Recumbent, no resistance to lateral positioning, does not react to hand clap 
 
4.6 Assessment of injection reaction 
Reactions to injection (not to needle insertion), were scored in study III according to Table 
4.  
Table 4. Injection reaction. 
0 = No reaction 
1 = Mild reaction, non-specific change in posture, subtle movement without specific 
attention to the injection site 
2 = Moderate reaction, specific change in posture and movement, specific attention to the 
injection site 
3 = Severe reaction, attempt to move away from injection, vocalization, aggression, biting, 
growling or barking 
 
4.7 Drug analyses  
In all of the studies, blood samples were collected into Ethylenediaminetetraacetic acid 
(EDTA) -tubes (Vacuette, Grainer Bio-One, NC, USA) for drug plasma concentration 
analyses at 30, 60, 120, 240 and 360 minutes after the drug injection (study I), 20 minutes 
after drug injection (study II) and within a 20 minute time frame (study III). Plasma samples 
were separated by centrifugation and frozen at -20 °C until analysed. In study II, after 
confirmation of euthanasia by auscultating the lack of heartbeat, the CNS was quickly 
removed. Exsanguination was not performed prior to sample collection. Prior to freezing, the 
dura mater was opened, and any remaining spinal fluid or blood was absorbed with a gauze 
from the tissue samples. Tissue samples were obtained from the lumbar and cervical spinal 
intumescences and from the brain; immediately frozen in liquid nitrogen and stored at -80 
°C. All drug analyses were performed with liquid chromatography tandem mass 
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spectrometry (LC-MS/MS). A summary of the drugs analysed in each study is presented in 
Table 5.  
In study I, the linear range of the assay was 25 ng/mL to 460 ng/mL. For quality control 
samples, the inter-assay accuracy (at 70, 250 and 380 ng/mL) was 94.4 % - 111.6 %. 
Validation was performed for range, precision, accuracy, carry-over, interference of 
analytes, internal standards and analyte stability for both analytical methods. The inter-
assay accuracy for quality control samples (at 70, 250 and 380 ng/mL) was 94.4 % - 111.6 
%. Validation was performed for range, precision, accuracy, carry-over, interference of 
analytes, internal standards and analyte stability for both analytical methods. For more 
details, see article I. 
 
Table 5. Summary of drug concentrations analysed with LC-MS/MS 
Study Drugs analysed Matrix of analysis 
I Dexmedetomidine, levomedetomidine, butorphanol, 
midazolam, vatinoxan 
Plasma  
II Dexmedetomidine, levomedetomidine, vatinoxan Plasma, tissue from 
the CNS 
III Medetomidine, butorphanol, vatinoxan. Plasma  
 
For the analysis of plasma samples in study II, dexmedetomidine, levomedetomidine and 
vatinoxan were combined into one working solution. Working solutions were formulated by 
dilution of stock solutions (1 mg/mL) with methanol to concentrations of 0.01, 0.1, 1, 10 and 
100 ng/µL. Calibrators were formulated at concentrations ranging from 0.1 to 2000 ng/mL. 
For each quantitative assay, fresh calibration curves and negative control samples were 
produced. For tissue sample analyses in study II, accuracy for QC samples was 89 - 107 % 
and imprecision was 3 - 6 % for all analytes. The technique was optimised to provide a 
quantitation limit of 0.5 ng/mL for dexmedetomidine and levomedetomidine and 0.1 ng/mL 
for vatinoxan. The detection limit was approximately 0.2 ng/mL for dexmedetomidine and 
levomedetomidine, and for vatinoxan it was 0.05 ng/mL.  
In study III, reference standards were prepared in dog plasma spiking with the analytes 
making a final concentration range of 0.02–20 000 ng/mL. The linear calibration ranges 
(ng/mL) were undiluted butorphanol 0.2500, diluted medetomidine 0.22000, and undiluted 
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vatinoxan 0.52000. The QC samples were in the range 94-116% of the nominal 
concentrations. For details, see Study III. 
Dexmedetomidine concentrations were analysed after solid phase extraction with Sep-Pak 
tC18 96 well extraction plates (Waters Co, MA, USA) and 4,5-diphenylimidazole (Sigma-
Aldrich, , MO, USA) was used as an internal standard.  
Tissues samples (230-890 mg) were weighed into 7 mL Precellys hard tissue homogenizing 
vials  (Bertin Corp,, MD, USA) and then placed into a freezer at -20 ºC for 10 minutes (study 
II). After this, samples were homogenized for 30 seconds at 5500 rpm in a Precellys 24 
tissue homogenizer (Bertin Corp., USA), followed by a 5-minute cool down period. Then 
samples were homogenized again at 15000 g for 2 minutes with 1 mL of CAN containing 
d4OHD and HEPS at 100 ng/mL. After this, 0.5 mL was transferred to a 13 X 100 mm glass 
tube and dried in nitrogen at 45 ºC. 
Samples were redissolved with 100 µL of 5% ammonium hydroxide and 500 µL of water in 
a saturated sodium chloride solution before adding 3 mL of methyl tert-butyl ether (MTBE). 
Samples were mixed by rotation for 20 minutes at 40 revolutions per minute. Following 
rotation, samples were centrifuged 4 ºC for 5 minutes at 2260 g. The top organic layer was 
moved to a glass tube. Again, samples were dried in nitrogen at 45 ºC and dissolved in 200 
µL of 20 mM ammonium formate with 0.1% diethylamine (DEA). The injection volume for 
LC-MS/MS system was 10 µL. Positive heated electrospray ionization at 300 ºC was used. 
TSQ Vantage triple quadrupole mass spectrometry (Thermo Scientific, CA, USA) was used 
for quantitative analysis of tissue, coupled with a turbulent flow chromatography system 
(TFC TLX2 Thermo Scientific, CA, USA) having LC-10ADvp LC systems (Shimadzu, Japan) 
that was operated in laminar flow mode. For a detailed description, see study II. Calibration 
curves and quantities of dexmedetomidine, levomedetomidine and vatinoxan in all samples 
were generated with Quanbrowser software (Thermo Fisher Scientific, USA). For all 
calibration curves, a weighting factor of 1/X was used. Accuracy for QC samples was 89 - 
107 % and imprecision 3 - 6 % for all analytes. The technique was optimized to provide a 
quantitation limit of 0.5 ng/mL for dexmedetomidine and levomedetomidine and 0.1 ng/mL 
for vatinoxan. The detection limit was around 0.2 ng/mL for dexmedetomidine and 
levomedetomidine, and for vatinoxan it was 0.05 ng/mL. 
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4.8 Statistical analyses 
In study I, a power calculation (http://hedwig.mgh.harvard.edu/sample_size/size.html) was 
derived from earlier results for Tmax of dexmedetomidine (Restitutti et al. 2017), butorphanol 
(Pfeffer et al. 1980), and midazolam (Schwartz et al. 2013) after IM administration in dogs. 
To detect a 50% decrease in T max, with a power of 80% and an alpha-level set at 0.05, with 
pairwise one-tailed one-way analysis of variance (ANOVA), three dogs were needed for 
midazolam, five  for dexmedetomidine and six  for butorphanol. For study II, the number of 
dogs was determined by the initial study (Heikkilä et al. 2018), so it could not be altered, and 
therefore the power analysis was not performed. For study III, power analysis was performed 
based on a mean HR of 40 bpm (MB) and 60 bpm. Standard deviation was set up at 15 
bpm, and with a power of 80% and an alpha-level set up at 0.05, 20 dogs were required for 
each treatment.  
In the study I and III, analyses were computed using SPSS Statistics version 24.0 for 
Windows (IBM). In study II, statistical analyses were performed with JMP Pro 12 (SAS 
Institute, NC, USA).  
For evaluation of the normality of data distribution, the Shapiro-Wilks test was used for 
studies I and III. In study II, non-parametric tests were used. Non-parametric tests were 
chosen for study II because the sample size was small, Irrespective of data distribution, non-
parametric tests are more conservative for the analysis of results.  
Repeated-measures ANOVA was used for analysis of HR (study I and III) and respiratory 
rates (III), and t-test followed by the Holm Bonferroni post hoc correction was used for 
comparisons between treatments and against baseline. 
Area under the time-concentration curves (AUC) were calculated with the trapezoidal 
method for sedation during certain time frames (AUCsed0-15) for the first 15 minutes in study 
I, and AUCVAS30 and AUCSDS30 for the first 30 minutes in study III). The Mann-Whitney U-test 
was used for the comparison of AUCVAS30 (study III), VAS scores and pale mucous 
membranes (III) and sedation scores (I) between treatments at each time point. Related 
Samples Friedman’s Two-Way of Analysis of Variance by Ranks with Holm Bonferroni 
correction was used for testing VAS and pale mucous membranes against baseline within 
each treatment (study III). Two-sided Fischer’s exact test was used to compare the need for 
additional medetomidine or atipamezole, presence of loose faeces, tiredness (residual 
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sedation) and decreased appetite. Independent samples T-test was used for plasma drug 
concentrations and time for “head down” (study III).  
Paired samples 1-tailed t-test was used for Cmax and Tmax, and 2-tailed t-testing was 
performed on AUC0-90 and AUCsed0-15 (study I). Friedman’s test was used to compare 
calculated tissue:plasma ratios between vatinoxan, levomedetomidine and 
dexmedetomidine, followed by a one-tailed Wilcoxon’s Rank Sum test with a Bonferroni post 
hoc correction. Two-tailed Wilcoxon’s Rank Sum test was used to compare plasma and 
tissue concentrations between dex- and levomedetomidine (study II).  
The alpha level was set to 0.05 in all studies. Data are presented as mean and standard 





In study I, the VAS sedation measurements are shown in Table 6. Peak sedation scores 
shown as median (range) was observed at 15 minutes for MBM-V and at 20 minutes for 
MBM (p = 0.109). AUCsed0-15 was significantly greater for MBM-V than MBM (p = 0.047). 
 
Table 6. Visual analogue scale (VAS) for sedation score (0 - 100) for treatments MBM 
and MBM-V.  
Data of VAS scores are reported as median (range). AUCsed0-15 (reported as mean ± 
standard deviation (SD)) were calculated for the first 15 minutes. Five dogs were given 
both treatments (study I). 
Time point (minutes) MBM MBM-V 
Before 0 (0 - 0) 0 (0 – 0) 
3 18 (0 – 20) 23 (3 – 85) 
6 14 (0 – 51) 84 (6 – 100) 
10  69 (22 – 97) 96 (72 – 100) † 
15 95 (17 – 100)  100 (96 – 100) † 
20  100 (58 – 100) † 100 (100 – 100) † 
25 100 (76 – 100) † 100 (100 – 100) † 
30  100 (79 – 100) † 100 (83 – 100) † 
40  96 (78 – 100) † 94 (87 – 100) † 
50 86 (77 – 100) † 78 (66 – 100)  
60 85 (70 – 100)  70 (50 – 78) 
90 68 (62 – 81)  26 (15 – 74)  
AUCsed0-15   598 ± 256 * 996 ± 261 * 
*Significant difference between treatments  
† Significant difference compared to baseline. 
 
In study II, all dogs became profoundly sedated after the treatment and spontaneously 
remained in lateral recumbency until euthanized. In the study III, AUCVAS was significantly 
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higher for the first 30 minutes in animals that were given vatinoxan (MBV) (p < 0.001). Data 
for VAS, AUCVAS and AUCSDS are presented in Table 7. VAS for MBV was significantly 
higher compared to baseline from 5 (p = 0.025) until 40 minutes (p < 0.001). VAS for MB, 
as well, was higher compared to baseline at 10-40 minutes (p < 0.001). More dogs in group 
MBV required additional medetomidine after 30 minutes (p = 0.023) and fewer dogs needed 
atipamezole (p < 0.001) than with MB.  
 
Table 7. The visual analogue sedation scores and area under the curve for visual 
analogue scale (VAS) sedation score-time (AUCVAS30) and simple descriptive score 
(AUCSDS30) for the first 30 minutes and. Data are reported as median (range). 
Time point (minutes) MB MBV 
0  
 
0 (0  0) 
n = 29 
0 (0 – 0) 
n = 27 
5  
 
58 (9  86) 
n = 28 
64 † (21 – 100) 
n = 27 
10  
 
96 † (31  100) 
n = 27 
100 † (51 – 100) 
n = 27 
20  
 
100 † (82  100) 
n = 28 
100 † (78 – 100) 
n = 27 
30  
 
100 † (83 – 100) 
n = 28 
100 † (71 – 100) 
n = 27 
40  
 
100 † (90  100) 
n = 26 
100 † (14 – 100) 
n = 25 
AUCVAS30   2445 * (1855 – 2585) 2555 * (1868 – 2750) 
AUCSDS30 98 (75 – 105) † 105 (73 – 110) † 
* Significant difference between treatments 
† Significant difference from baseline 
 
5.2 HR 
In study I, HR was significantly higher after MBM-V than MBM between 20 and 90 minutes 
(Figure 3, upper picture). In study III, HRs were significantly lower with both treatments 
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compared to baseline. HR was significantly higher between 10-40 minutes with MBV than 
MB. HRs are reported until 40 minutes (Figure 3, lower picture): at that time point data from 
two dogs were missing from both groups [procedure had already ended (n = 1 in both 
groups) and one dog had needed additional sedation (n = 1 in both groups)]. The lowest 
HRs detected after additional medetomidine was 28 beats per minute (bpm) with MB (n = 1) 
and 34 bpm with MBV (n = 7). The ranges in HRs after additional medetomidine were 
between 28 - 36 bpm in MB and 34 - 68 bpm in MBV.   
 
 
Figure 3. Heart rate after IM administration of MBM and MBM-V drug combinations 
(study I, upper picture). In study III, heart rates were reported until 40 minutes after 
injection of MB or MBV for dogs that were not given additional medetomidine or 
atipamezole (lower picture). * Significant difference between treatments. 
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5.3 Concentrations of drugs in plasma and tissue 
Plasma concentrations of levomedetomidine, dexmedetomidine, butorphanol, midazolam 
and vatinoxan are presented in Figures 4 - 8. Table 8 summarizes Cmax, Tmax and area under 
curve for the first 90 minutes (AUC0-90) for these drugs. Tmax of midazolam and 
levomedetomidine were significantly earlier after MBM-V. The other analytes showed a 
tendency towards higher Cmax and smaller Tmax after MBM-V compared to MBM.  
Table 8. Observed peak drug concentrations in plasma (Cmax), the time of maximum drug 
concentration in plasma (Tmax) and area under the concentration-time curve (AUC). Shown 
as mean ± SD and minimum and maximum in paretheses. 
* Significant difference between treatments 









MBM 4.3 ± 2.0 
(0.9 – 6.0) 
27 ± 15 
(10 – 50) 
216 ± 92 
(54 – 279) 
MBM-V 6.6 ± 2.6 
(3.7 – 10.8) 
17 ± 4.5 
(10 – 20) 
247 ± 65 
(144 – 307) 




MBM 2.7 ± 1.3 
(0.5 – 3.7) 
32 ± 15 
(10 – 50) 
140 ± 63 
(30 – 181) 
MBM-V 4.6 ± 1.6 
(2.6 – 6.7) 
18 ± 6 
(10 – 25) 
178 ± 47 
(107 – 227) 




MBM 10.7 ± 6.1 
(1.7 – 16.9) 
27 ± 4.5 
(10 – 30) 
589 ± 305 
(116 - 886) 
MBM-V 19.9 ± 9.6 
(10.5 – 34.0) 
15 ± 5 
(10 – 20) 
818 ± 246 
(535 – 1143) 




MBM 82.2 ± 43.9 
(12.9 – 134.0) 
23 ± 9 
(10 – 40) 
3743 ± 1886 
(749 – 5837) 
MBM-V 157.8 ± 95.8 
(82.9 – 300.2) 
11 ± 6 
(6 – 20) 
5644 ± 2213 
(3920 – 8900) 
p-value 0.11 0.049 * 0.33 
Vatinoxan MBM-V 907 ± 173 
(672 – 1051) 
23 ± 6 
(15 – 30)  
62755 ± 11268 




Figure 4. Dexmedetomidine concentrations in plasma after administration of 1) medetomidine 
hydrochloride (20 μg/kg) + butorphanol (100 μg/kg) + midazolam (200 μg/kg) IM (MBM), and; 
2) medetomidine (20 μg/kg) + vatinoxan hydrochloride (500 μg/kg) + butorphanol (100 μg/kg) 
+ midazolam (200 μg/kg) IM (MBM-V). Data from five dogs are shown. Both treatments were 
administered at 0 minutes. Data are shown as mean and standard deviation (SD). 
 
 
Figure 5. Levomedetomidine concentrations in plasma after administration of 1) 
medetomidine hydrochloride (20 μg/kg) + butorphanol (100 μg/kg) + midazolam (200 μg/kg) 
IM (MBM), and; 2) medetomidine (20 μg/kg) + vatinoxan hydrochloride (500 μg/kg) + 
butorphanol (100 μg/kg) + midazolam (200 μg/kg) IM (MBM-V). Data from five dogs are shown. 










































































Figure 6. Butorphanol concentrations in plasma after administration of 1) medetomidine 
hydrochloride (20 μg/kg) + butorphanol (100 μg/kg) + midazolam (200 μg/kg) IM (MBM), and; 
2) medetomidine (20 μg/kg) + vatinoxan hydrochloride (500 μg/kg) + butorphanol (100 μg/kg) 
+ midazolam (200 μg/kg) IM (MBM-V). Data from five dogs are shown. Both treatments were 
administered at 0 minutes. Data are shown as mean and standard deviation (SD). 
 
 
Figure 7. Midazolam concentrations in plasma after administration of 1) medetomidine 
hydrochloride (20 μg/kg) + butorphanol (100 μg/kg) + midazolam (200 μg/kg) IM (MBM), and; 
2) medetomidine (20 μg/kg) + vatinoxan hydrochloride (500 μg/kg) + butorphanol (100 μg/kg) 
+ midazolam (200 μg/kg) IM (MBM-V). Data from five dogs are shown. Both treatments were 

































































Figure 8. Vatinoxan concentrations in plasma after administration of 1) medetomidine 
hydrochloride (20 μg/kg) + butorphanol (100 μg/kg) + midazolam (200 μg/kg) IM (MBM), and; 
2) medetomidine (20 μg/kg) + vatinoxan hydrochloride (500 μg/kg) + butorphanol (100 μg/kg) 
+ midazolam (200 μg/kg) IM (MBM-V). Data from five dogs are shown. Both treatments were 
administered at 0 minutes. Data are shown as mean and standard deviation (SD). 
 
Data from one of the six dogs had to be excluded from study I because low concentrations 
of vatinoxan (9.59 - 36.5 ng/mL) were found in its blood samples also after MBM treatment. 
The reason for this contamination with vatinoxan could not be detected. 
 
For study II, the concentrations for dexmedetomidine, levomedetomidine and vatinoxan and 
calculated ratios between plasma versus brain and cervical and lumbar spinal cord are 
summarized in Table 9. No macroscopic findings indicative of subclinical disease were 



































Table 9. Concentrations of dexmedetomidine (DEX), levomedetomidine (LEVO), 
vatinoxan (VAT) and VAT/DEX ratio [shown as median (minimum and maximum 
range)] in plasma, brain, and cervical (c) and lumbar (l) spinal cord. The 








6.8 (5.9 - 7.8) 
 
4.1 (3.4 - 5.2) 
 
1380 (701 -2440) 
 
202 (115 - 323) 
Brain 
(ng/g) 
29.9 (27.1 - 39.7) 28.2 (22 - 37.3) 27.5 (15.6 - 44.3) 0.8 (0.65-1.53) 
Spinal cord (c)  
(ng/g) 
23.3 (17.8 - 31.2) 18.5 (15.4 - 27.8) 17.2 (12.7 - 20.6) 0.7 (0.6 - 0.88) 
Spinal cord (l)  
(ng/g) 
22 (14.5 - 31.3) 17.8 (12.9 - 31) 20 (12.4 - 28.3) 0.9 (0.73 - 1.2) 
Ratio  
plasma/brain 








0.3 (0.22 - 0.36) 0.2 (0.17 - 0.31) 63.3 (56.5 - 97.2)  
 
In study III, plasma concentrations of both medetomidine and butorphanol (Figures 9 and 
10) were significantly higher with MBV (p < 0.001) in samples collected between 11 and 18 
minutes after drug injection. Vatinoxan plasma concentration in MBV-treated dogs was 607 




Figure 9. Plasma concentrations of medetomidine in 56 pet dogs undergoing sedation with 
either MB (n = 29) or MBV (n = 27) for radiography. Plasma concentrations are reported as 
mean ± standard deviation (SD). * Significant difference between treatments. 
 
 
Figure 10. Plasma concentrations of butorphanol in 56 pet dogs undergoing sedation with 
either MB (n = 29) or MBV (n = 27) for radiography. Plasma concentrations are reported as 









































































Other results from study III are presented in Table 10. “Head down” time, mucous membrane 
colour, requirement for additional medetomidine or atipamezole, duration of required 
sedation, tiredness (residual sedation), loose faeces, decrease in appetite, number of blood 
samples analysed and sampling time are presented in Table 10. No significant differences 
were detected between treatments in injection reactions (p = 0.117) (Study III). 
 
Table 10. Results for 56 client-owned dogs undergoing sedation with either MB (n = 29) 
or MBV (n = 27) for radiography. 
 MB MBV p-value 
Head down (seconds)  
(mean ± standard deviation, SD) 
298 ± 74 
 
241 ± 78 0.012 
Additional medetomidine (number of dogs)  
(administration time in minutes,  
mean ± standard deviation, SD) 
1 (30) 7 (53 ± 10) 0.023 
Atipamezole administration  
(number of dogs)  
26  12  < 0.001 
Duration of required sedation  
(minutes, mean ± standard deviation, SD) 
66 ± 14.5 66 ± 19  
Lethargy (number of dogs)  26 17 0.221 
Loose faeces (number of dogs)  7 9 0.558 
Decrease in appetite (number of dogs)  2 3 0.664 
Blood sample analysed (number of dogs)  23 25  
Blood sampling time (minutes, range) 13 (11  15) 13.5 (12  18) 0.36 
Tiredness, loose faeces and decrease in appetite reported by owners. 






6.1 Intramuscular absorption 
Studies I and III were designed to investigate how the addition of vatinoxan to a combination 
of sedative drugs would affect the IM absorption of the concomitantly administered drugs. 
The IM route was chosen for its practicality and its clinical relevance. The main finding was 
that the addition of vatinoxan to the sedative combination increased the absorption of both 
medetomidine and other concomitantly given drugs, such as butorphanol (I, III) and 
midazolam (I) after IM administration. This is clinically relevant as it may suggest a need for 
adjustment of drug doses when they are used concomitantly with vatinoxan. The results 
from study I suggest that the pharmacological drug interactions induced by α2-adrenoceptor 
agonists and their antagonists began during the drug absorption phase from the 
extravascular site of administration. The alleviation of α2-adrenoceptor agonist-induced 
vasoconstriction probably leads to improved perfusion within the muscle, and therefore 
increases drug uptake into the circulation. It has been speculated that the improved 
absorption seen with the administration of vatinoxan is caused by inhibition of the local 
vasoconstrictive effect   medetomidine at the site of the injection (Restitutti et al. 2017). 
Butorphanol (I, III) and midazolam (I) were used as marker molecules to describe the effects 
of medetomidine and vatinoxan on IM absorption of concomitantly given drugs. These two 
drugs were chosen for their common use in veterinary medicine in combination with α2-
adrenergic agonists. Both of the drugs are short-acting and both are rapidly absorbed 
following IM injection. Butorphanol is a synthetic ĸ-agonist-µ-antagonist opioid (Raffe 1989, 
Hosgood 1990, Commiskey et al. 2005) that is often combined with α2-adrenoceptor 
agonists to improve the quality of sedation in dogs (Ko et al. 1996, Pypendop et al. 1996, 
Kuo & Keegan 2004). Midazolam, is a benzodiazepine which induces muscle relaxation and 
tranquillisation in dogs (Gross et al. 1990), and therefore it is often combined with α2-
adrenergic agonist for minor procedures (Verstegen & Petcho 1993, Pypendop et al. 1996, 
Itamoto et al. 2000). These marker molecules revealed that α2-adrenoceptor agonists and 
antagonists may also affect the absorption of other simultaneously administered drugs 
(study I). 
In linear pharmacokinetics, the T1/2 elimination half-life of a drug molecule is constant, and 
not dependent on the absorption phase. However, this is not always true. Flip-flop 
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pharmacokinetics describe a situation, where following extravascular dosing the rate of 
absorption of a drug is slower than its elimination, as reported here with medetomidine when 
it is administered IM without vatinoxan (Study I, Restitutti et al. 2017). Since the elimination 
cannot take place before the drug is in systemic circulation, the decrease in the terminal 
slope of the concentration curve depends greatly on how quickly the drug is absorbed 
(Yáñez et al. 2011). Since vatinoxan accelerates the absorption of concomitantly given 
drugs after IM injection, it also seems to affect the elimination rate of medetomidine (study 
I, Restitutti et al. 2017) more so than reported following IV injection (Honkavaara et al. 2012, 
Bennett et al. 2016).  
 
6.2 Sedation and other central effects of vatinoxan 
The distribution of vatinoxan to both brain and spinal cord was poor in dogs, whereas 
enantiomers of medetomidine concentrated in the CNS (study II). The brain:plasma ratio for 
vatinoxan was 0.02 (0.01-0.04) in dogs (study II), which was  comparable to results  reported 
for marmosets (0.04) and rats (0.06) (Clineschmidt et al. 1988). Salonen et al. (1989) also 
reported that medetomidine concentration in rat brain was significantly higher compared to 
plasma 20 minutes after subcutaneous administration. Concentrations of medetomidine and 
vatinoxan in spinal cord have not been reported previously in dogs or other species. The 
results of study II confirm the peripheral distribution of vatinoxan in dogs. This has already 
been proposed earlier since vatinoxan alleviates the peripheral effects of α2-adrenoceptor 
agonists without affecting their centrally mediated effects in dogs (Enouri et al. 2008, 
Honkavaara et al. 2011, Restitutti et al. 2017).  
In studies I and III, vatinoxan intensified the early-stage sedation and shortened its duration 
in dogs. In all studies, reliable clinical sedation was achieved both in the presence (study I, 
II and III) and in the absence (studies I and II) of vatinoxan. The changes in the depth of 
sedation, when vatinoxan was added to the IM administered sedative combination, may be 
divided into two phases. Firstly, the onset of sedation was faster (study III). The overall 
sedative effect was also significantly greater during the first 15 (study I) or 30 (study III) 
minutes when vatinoxan was administered IM in the same syringe with other drugs. 
Secondly, the presence of vatinoxan shortened the duration of sedation (studies I and III). 
Similar findings were reported by Restitutti et al. (2017), who also detected that the time-
concentration curves of dexmedetomidine in plasma intersected approximately 30 minutes 
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after IM administration of medetomidine and medetomidine-vatinoxan. Prior to the 30-
minute time point the plasma concentration of dexmedetomidine (stereoisomer 
dexmedetomidine was analysed although medetomidine was administered) was higher in 
the presence of vatinoxan, whereas after this time point, the concentrations of 
dexmedetomidine in plasma were higher in dogs given medetomidine alone (Restitutti et al. 
2017). The drug concentrations in plasma detected in studies I and III agreed with these 
earlier results (Restitutti et al. 2017).  
The impact of vatinoxan on α2-adrenoceptor agonist-induced sedation appears to be 
minimal  and related to  its effects on the disposition of co-administered drugs via the IM 
route in dogs (Restitutti et al. 2017), cats (Pypendop et al. 2017, Honkavaara et al. 2017), 
and sheep (Adam et al. 2018). Since the addition of vatinoxan to the sedative combination 
of medetomidine-butorphanol or medetomidine-butorphanol-midazolam shortens the 
duration of the sedation, it may be beneficial to consider additional sedative strategies in 
animals requiring longer sedation. However, in the presence of vatinoxan, a deep level of 
sedation is usually achieved during the initial 20-30 minutes. The sedation develops 
between 5 and 10 minutes after IM injection (studies I and III). This time frame is usually 
sufficient for minor procedures, such as routine diagnostic imaging. 
Bennett et al. (2017) speculated that active transport out of the cell might play some role in 
the efflux of vatinoxan through the BBB, in which transporters other than P-gp could be 
involved. If an efflux transporter were involved in this process, a high concentration of 
vatinoxan could occur within the CNS. This in turn might prevent or reverse the sedation 
induced by α2-adrenoceptor agonists in animals with a mutation in the gene encoding that 
specific protein.  In study III, it would have been interesting to analyse DNA-samples from 
the individual dogs since many breeds, such as for an example Border Collies, were 
represented, some of which are known to carry the ABCB1-gene defect (Mealey et al. 2001, 
Neff et al. 2004, Mealey et al. 2008). If any of these individuals had been homo- or 
heterozygous for the mutation in the ABCB1-gene the length and depth of sedation or 
recovery in dogs may have been apparent. Although, multiple individuals from many herding 




Medetomidine-induced bradycardia was apparentafter IM administration of medetomidine-
vatinoxan in studies I and III.  After the absorption phase, vatinoxan attenuated the 
bradycardia, but in the first 5-10 minutes the decrease in HR caused by medetomidine was 
evident after both treatments (studies I and III). The initial decrease in HR in dogs given 
vatinoxan may have been caused by the more rapid absorption of medetomidine in the 
presence of vatinoxan (Restitutti et al. 2017). Restitutti et al. (2017) also reported the initial 
bradycardia after medetomidine, but the classical cardiovascular changes, such as 
reduction in HR, CO and increase in central venous pressure, were attenuated by vatinoxan.  
In the first study, the initial bradycardia was evident probably due to the higher plasma 
concentrations of dexmedetomidine in the presence of vatinoxan. The Tmax of 
dexmedetomidine occurred at approximately 15 minutes, whereas the Tmax of vatinoxan was 
approximately 25 minutes (Study I, Restitutti et al. 2017). Therefore, the early concentration 
of vatinoxan may not have been sufficiently high to compete with dexmedetomidine at 
peripheral α2-adrenoceptors and prevent the initial bradycardia seen in study I. Hence, when 
dexmedetomidine is absorbed more rapidly in the presence of vatinoxan, the α2-
adrenoceptor-induced bradycardia may be even more prominent than that reported in the 
absence of vatinoxan. If vatinoxan were given prior to the administration of an α2-
adrenoceptor agonist, it could reach peripheral vascular adrenoceptors before the agonist 
and alleviate even the initial vasoconstriction and baroreflex-mediated bradycardia. In dogs 
given vatinoxan as a pretreatment 30 minutes before administration of 5 µg/kg of 
dexmedetomidine, vatinoxan prevented the immediate pressor effects of dexmedetomidine 
and no significant difference in HR was detected at 5 and 60 minutes after dexmedetomidine 
(Pagel et al. 1998). Additionally, when these drugs were given at the same time, but injected 
into different muscles, the concurrent IM administration of vatinoxan and medetomidine 
performed at least as well as IV route for attenuation of cardiovascular changes caused by 
medetomidine (Rolfe et al. 2012).  
Vatinoxan alleviated medetomidine-induced bradycardia in healthy dogs, but even with 
vatinoxan present, HRs were lower than baseline. With medetomidine, HRs were 
approximately 40 bpm whereas in medetomidine-vatinoxan-treated dogs, they were 
approximately 60 bpm. Commonly 50 to 60 bpm is regarded as the threshold for bradycardia 
in large dogs, and 70 bpm in small breed dogs (Thurmon et al. 2007, Brodbelt et al. 2008). 
57 
In studies I and III, HRs were often below these thresholds, even with vatinoxan. However, 
Hall et al. (1991) reported very low resting HRs in adult clienbt-owned dogs of various 
breeds. During natural sleep minimum HRs ranging between 17 and 46 bpm were detected 
with ambulatory electrocardiography. Cruz et al. (2017) also reported mean minimum heart 
rates below 50 bpm in healthy adult dogs. In beagles, nightly HRs between 60 and 70 bpm 
have been reported previously (Nolan et al. 2004, Honkavaara et al. 2008). Results from the 
previous studies performed in dogs during their physiological sleep may indicate that 
healthy, adult dogs are able to tolerate HRs below the recognised thresholds indicative of 
bradycardia. 
In laboratory beagles, arterial and central venous pressures were significantly lower and 
closer to the physiological status following the administration of medetomidine-butorphanol-
vatinoxan IM compared to medetomidine-butorphanol-treatment (Salla et al. 2014b). Salla 
et al. (2014b) did not detect hypotension in dogs given medetomidine-butorphanol-vatinoxan 
following IM or IV administration. Meanwhile after medetomidine-butorphanol-treatment 
dogs had significantly higher MAPs for the first 30 minutes after IM injection. Furthermore, 
vatinoxan alleviated the cardiovascular effects of medetomidine specifically changes in HR, 
cardiac index and oxygen delivery index were significantly higher after both IM and IV 
administration routes in dogs given vatinoxan (Salla et al. 2014b). Since only HRs were 
reported in studies I and III, without data on blood pressure or any other cardiovascular 
variables, aside from the colour of the mucous membranes in study III, it cannot be proven 
that the alleviation of the medetomidine-induced bradycardia actually improved cardiac 
function. However, it may be speculated that the alleviation of vasoconstriction could have 
resulted in hypotension in studies I and III.   This may have overridden the beneficial effects 
of a higher HR in vatinoxan-treated dogs compared to dogs given medetomidine without 
vatinoxan. However, the findings reported by Salla et al (2014b) indicate that the detected 







6.4 Adverse effects of vatinoxan 
In study III, the most frequently observed side-effect after sedation was loose faeces. All 
dogs expressing loose faeces were administered either atipamezole, vatinoxan or both. The 
adrenergic regulation of gastrointestinal motility and secretions is mainly related to α2-
adrenoceptors (Virtanen & McDonald, 1987). Prolonged intestinal transit time (Ruwart et al. 
1980) and inhibition of gastric acid secretion in rats (Del Tacca et al. 1982) and dogs (Soldani 
et al. 1984) induced by α2-adrenoceptor agonists have been demonstrated. These effects 
were inhibited by α2-adrenoceptor antagonists such as atipamezole (Virtanen & McDonald, 
1987). Atipamezole restores intestinal motility and induces defaecation in dogs after α2-
adrenoceptor agonist-induced sedation (Maugeri et al. 1994) and vatinoxan seems to have 
a similar effect (study III). When both of these drugs (atipamezole and vatinoxan) are given, 
it may further enhance gastrointestinal motility. Hence, it would be beneficial to inform the 
owners about this possible adverse effect after administration of α2-adrenoceptor 
antagonists (study III). 
In studies I and III, dogs were studied at ambient room temperatures of and they maintained 
normal body temperature without active warming and there were no significant differences 
between treatments. However, as reported by Vainionpää et al. (2013), the alleviation of 
vasoconstriction by vatinoxan may lead to increased core heat loss in dogs handled at 
similar room temperatures to those used in studies I and III. Therefore, in clinical work, it is 
essential to monitor the body temperature in sedated and anaesthetized dogs, since 
vatinoxan-treated dogs may be prone to hypothermia (Vainionpää et al. 2013). 
 
6.5 Methodological considerations and limitations of the 
studies 
In studies I and III, power analyses were performed, and the number of dogs included in 
were expected to provide sufficient statistical power to avoid type II errors. Unfortunately, in 
study I, one of the six beagles had to be excluded due to technical failure. Therefore, a larger 
sample size was required in study I, to increase statistical power. Had the sample size been 
higher, more the differences in Tmax and Cmax of dexmedetomidine and butorphanol may 
have been statistically significant as well. In study I, at the time of administration, the 
temperature of the drug combination was not measured. Differences in the temperature of 
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the two solutions may have affected the absorption rate from the site of injection. Although, 
with both treatments the drugs were handled in the same manner, and held in a hand warm 
water bath, so it is unlikely that  the outcome would have differed between these two 
treatments.  
There were some limitations in study II. After euthanasia, exsanguination was not 
performed. Therefore, contamination of tissue samples with blood may have resulted in 
higher concentrations of vatinoxan, thus narrowing the difference between the plasma and 
CNS drug concentrations. Hence, The   plasma:brain ratio of vatinoxan in study II may have 
been greater than reported here However, the very low concentration of vatinoxan in the 
CNS did not confirm lack of pharmacological action per se. It is remains unclear what CNS 
concentration of vatinoxan fails to produce a clinically relevant competition with 
dexmedetomidine at central adrenoreceptors. Further studies are required to determine the 
role of active transporters in the influx and efflux of vatinoxan to and from the CNS. 
Additionally, it would have been beneficial to determine the plasma and CNS concentrations 
of the individual drugs when administered as a sole agent.  
There was only one time point reported for drug plasma concentrations in studies II and III. 
Blood samples taken at multiple time points would have provided additional information 
about absorption and distribution, but the protocol of the studies limited the possibility for 
this (scheduled euthanasia in study II versus client-owned dogs in study III).  
In study III, it would have been useful to measure arterial blood pressures, even if non-
invasively, to verify the alleviation of the α2-adrenoceptor agonist-induced vasoconstriction 
by vatinoxan. This would also have indicated if hypotension occurred in dogs given a drug 
combination including vatinoxan. We did not demonstrate any improvement in CO. Since 
the alleviation of medetomidine induced vasoconstriction by vatinoxan may have resulted in 
hypotension, which could have overridden the beneficial effects of the higher HRs in dogs 
treated with the medetomidine-butorphanol-vatinoxan combination. 
The studies presented special ethical considerations. Trials were planned on the basis that 
the laboratory beagles used in study I would be rehomed without any permanent or lasting 
physiological effects. When designing the studies, the focus was to limit the stress 
experienced by the dogs, and thereby to minimize the associated elevation in their 
endogenous catecholamine concentrations. Dogs in study II were euthanized for other 
purposes and the protocol was applied solely to facilitate their terminal anaesthesia (Heikkilä 
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et al. 2018). Dogs in study III were pet dogs admitted for routine diagnostic imaging;  no 
surgical or otherwise painful procedures, aside from injecting the sedative combination IM 
and obtaining IV access for blood sample collection a, were performed.  
 
6.6 Clinical implications and future prospects 
Study III was the first published report where pet dogs of various breeds were treated with 
medetomidine and vatinoxan. Based on those results, vatinoxan proved to be clinically 
usable for healthy dogs as a part of a sedative combination for minor procedures since it 
alleviates medetomidine-induced bradycardia. No significant differences were detected in 
the number and type of side-effects that occurred in dogs given vatinoxan (MBV) compared 
to dogs administered MB. With respect to clinical use, the shorter onset of sedation and 
higher peak concentrations of drugs in plasma should be noted. This is beneficial as the 
preparation for the procedure can be started sooner. On the contrary, the shortened duration 
of sedation needs to be considered when planning the protocol for the sedation. 
Since the alleviation of the undesirable cardiovascular effects of α2-adrenoceptor agonists 
can be achieved with the use of vatinoxan (studies I, III), it may widen the spectrum of dogs 
and clinical conditions, for which α2-adrenoceptor agonists can be used. Further studies are 
required in dogs that are not deemed clinically healthy, since vatinoxan has not been studied 
in dogs that have systemic disease. Additionally, further studies investigating the use of 
vatinoxan as a part of an anaesthetic protocol for surgical procedures are required, as these 
findings have not yet been reported. Specifically, the effect of vatinoxan on antinociceptive 




1. Vatinoxan increased early plasma concentrations of concomitantly IM administered 
drugs by accelerating the absorption, probably by reversing α2-agonist-evoked 
vasoconstriction. This resulted in an increase in the early plasma concentrations of 
medicines (I, III). 
2. Low brain concentration and high plasma concentration of vatinoxan confirmed its 
peripheral disposition. On the contrary, the enantiomers of medetomidine, dex- and 
levomedetomidine, had higher concentrations in brain than in plasma. This finding 
explains why vatinoxan alleviated peripheral adverse effects of α2-adrenoceptor 
agonists without affecting their CNS effects in dogs (II).  
3. Vatinoxan intensified the early-stage sedation and shortened its duration as well as 
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